EP1636251A4 - Ccn1 compositions and methods - Google Patents

Ccn1 compositions and methods

Info

Publication number
EP1636251A4
EP1636251A4 EP04809453A EP04809453A EP1636251A4 EP 1636251 A4 EP1636251 A4 EP 1636251A4 EP 04809453 A EP04809453 A EP 04809453A EP 04809453 A EP04809453 A EP 04809453A EP 1636251 A4 EP1636251 A4 EP 1636251A4
Authority
EP
European Patent Office
Prior art keywords
ccn1
compositions
methods
ccn1 compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04809453A
Other languages
German (de)
French (fr)
Other versions
EP1636251A2 (en
Inventor
Lester F Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Munin Corp
Original Assignee
Munin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Munin Corp filed Critical Munin Corp
Publication of EP1636251A2 publication Critical patent/EP1636251A2/en
Publication of EP1636251A4 publication Critical patent/EP1636251A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP04809453A 2003-06-20 2004-06-21 Ccn1 compositions and methods Withdrawn EP1636251A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48016103P 2003-06-20 2003-06-20
PCT/US2004/019766 WO2005040191A2 (en) 2003-06-20 2004-06-21 Ccn1 compositions and methods

Publications (2)

Publication Number Publication Date
EP1636251A2 EP1636251A2 (en) 2006-03-22
EP1636251A4 true EP1636251A4 (en) 2009-07-29

Family

ID=34519960

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04809453A Withdrawn EP1636251A4 (en) 2003-06-20 2004-06-21 Ccn1 compositions and methods

Country Status (5)

Country Link
EP (1) EP1636251A4 (en)
CN (1) CN1835763B (en)
HK (1) HK1095743A1 (en)
TW (1) TWI356097B (en)
WO (1) WO2005040191A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022511A1 (en) 2007-08-06 2009-02-11 Corlife GbR Bioactive coating for an implantable device or bioprosthesis
SG188098A1 (en) 2008-01-30 2013-03-28 Geron Corp Synthetic surfaces for culturing stem cell derived cardiomyocytes
KR101635750B1 (en) 2008-01-30 2016-07-04 아스테리아스 바이오세라퓨틱스, 인크. Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
US20110183418A1 (en) * 2009-07-29 2011-07-28 Arthur Winston Martin Peptide-Polymer Cell Culture Articles and Methods of Making
CN104749371B (en) * 2013-12-30 2016-09-28 神州细胞工程有限公司 People's nephroblastoma overepressed gene encoding proteins enzyme linked immunological kit
CN105396136B (en) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1（Cyr61）Application in treatment skin injury and atrophoderma relevant disease
CN107312864B (en) * 2017-08-14 2021-03-05 中国医学科学院北京协和医院 WISP3 gene mutation for PPD auxiliary diagnosis and application thereof
CN107505462A (en) * 2017-08-14 2017-12-22 上海市同仁医院 A kind of Cyr61 protein detection kits and its application method
WO2019221576A1 (en) * 2018-05-17 2019-11-21 광주과학기술원 Pharmaceutical composition comprising ccn5 as active ingredient, for preventing or treating retinal diseases
CN114324526B (en) * 2021-12-27 2023-06-27 青岛农业大学 Biosensor for detecting prostate specific antigen in human serum and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055210A2 (en) * 2000-01-31 2001-08-02 Munin Corporation Human cyr61
US6413735B1 (en) * 1996-03-15 2002-07-02 Munin Corporation Method of screening for a modulator of angiogenesis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1071954A (en) * 1992-11-20 1993-05-12 沈阳市胸科医院 Method for pretreatment of specimen used in examining tubercle bacillus by polyase chain reaction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413735B1 (en) * 1996-03-15 2002-07-02 Munin Corporation Method of screening for a modulator of angiogenesis
WO2001055210A2 (en) * 2000-01-31 2001-08-02 Munin Corporation Human cyr61

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LAU L F ET AL: "The CCN family of angiogenic regulators: the integrin connection", EXPERIMENTAL CELL RESEARCH, ACADEMIC PRESS, US, vol. 248, 1 January 1999 (1999-01-01), pages 44 - 57, XP002272896, ISSN: 0014-4827 *
LEU S-J ET AL: "Identification of a novel integrin alpha6beta1 binding site in the angiogenic inducer CCN1 (CYR61)", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 278, no. 36, 5 September 2003 (2003-09-05), pages 33801 - 33808, XP002278880, ISSN: 0021-9258 *
LEU S-J ET AL: "Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphabeta3 and alphabeta1 in human umbilical vein endothelial cells", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 277, no. 48, 29 November 2002 (2002-11-29), pages 46248 - 46255, XP003017018, ISSN: 0021-9258 *
NICOLAUS B J R: "SYMBIOTIC APPROACH TO DRUG DESIGN", DECISION MAKING IN DRUG RESEARCH, XX, XX, 1 January 1983 (1983-01-01), pages 173 - 186, XP001111439 *

Also Published As

Publication number Publication date
HK1095743A1 (en) 2007-05-18
CN1835763B (en) 2011-04-20
TWI356097B (en) 2012-01-11
EP1636251A2 (en) 2006-03-22
WO2005040191A3 (en) 2006-03-23
CN1835763A (en) 2006-09-20
TW200513531A (en) 2005-04-16
WO2005040191A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
AP2089A (en) Compositions and methods for combination antiviraltherapy
GB0411940D0 (en) Methods and compositions
EP1701725A4 (en) Methods and compositions
EP1619947A4 (en) Antibacterial methods and compositions
ZA200602885B (en) Antimicrobial compositions and methods
HK1095743A1 (en) Ccn1 compositions and methods ccn1
EP1646382A4 (en) Compounds, compositions and methods
EP1692112A4 (en) Compounds, compositions, and methods
EP1692131A4 (en) Methods and compositions for slowing aging
IL219406A0 (en) Antiloading compositions and methods of selecting same
GB0305941D0 (en) Composition
AU2003256805A8 (en) Compounds compositions and methods
GB0302738D0 (en) Composition
TWI348479B (en) Impact-modified compositions and method
EP1684771A4 (en) Composition and method
GB0303609D0 (en) Novel therapeutic method and compositions
EP1675834A4 (en) Compounds, compositions, and methods
EP1594849A4 (en) Compounds, compositions, and methods
EP1680420A4 (en) Compounds, compositions, and methods
EP1620092A4 (en) Compounds, compositions, and methods
EP1608970A4 (en) Ccn3 compositions and methods
EP1706111A4 (en) Compounds, compositions and methods
GB0327050D0 (en) Therapeutic methods compositions and uses
EP1622878A4 (en) Compounds, compositions and methods
GB0325942D0 (en) Compositions and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060104

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/00 20060101ALI20060807BHEP

Ipc: A61K 38/00 20060101AFI20060807BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090625

17Q First examination report despatched

Effective date: 20100129

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110930